TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

The following data/materials will be collected for this registry study:

Clinical Data: Demographic data, date of diagnosis, pathology, radiological imaging at
diagnosis and relapse, signs and symptoms at diagnosis, molecular and biological data,
staging details including sites of disease, detailed treatment data (e.g. types and dates of
surgeries/interventional therapy (if any), medical/systemic therapy, radiotherapy), response
to treatment, dates of progression, types of progression (local or metastatic), and follow-up
data. The demographic and clinical data collected are abstracted and entered into an
electronic data system secured by password protection (see section 4.3.3). Collection of
existing molecular and/or genomic data or analysis that has been performed will also be
included.

Research Specimens:

Tissue (fresh/frozen/FFPE) will be requested for all enrolled patients and sent for central
review to study pathologist. Then tissue will be stored at CCHMC and future research testing
may be conducted on this tissue.

Optional research specimens:

Pending consent specification of family/patient, and resources, specimens may be sent
directly to collaborating laboratories to proceed with tumor modeling and drug testing, or
other translational research with PI or designee via an IRB approved project.

- Tumor Modeling (Fresh, frozen,): Prospectively collect or retain left-over tumor tissue
samples and normal tissue (background kidney) as available, for research purposes.

- Blood: prospectively collected at time of enrollment and at time of relapse

- Urine: prospectively collected at time of enrollment and at time of relapse

Registry clinical data will be correlated with biological/bioinformatic and genomic data.
Data stored in the Registry may be used to provide statistical data for scientific
presentations and for preparation of peer-reviewed manuscripts. For such purposes all data
will be de-identified. Beyond tumor model development and new agent drug testing (if selected
in the consent process), data and specimens will be released for IRB approved research
proposals upon approval from the TFE RCC Steering Committee.

Inclusion Criteria:

- All patients of any age with a diagnosis of a TFE Renal Cell Carcinoma.

- Unless the patient is deceased, all patients and/or one parent or legal guardian must
provide written informed consent as well as HIPAA/release of information consent.

Exclusion Criteria:

- Any patient that has not been diagnosed with TFE Renal Cell Carcinoma